-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Khiron Completes Acquisition Of Pharmadrug Production, Expanding Its Presence In Europe
Khiron Completes Acquisition Of Pharmadrug Production, Expanding Its Presence In Europe
Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX:KHRNF) (Frankfurt:A2JMZC) has completed the acquisition of Pharmadrug Production GmbH from Pharmadrug Inc. (OTCQB:LMLLF) (CSE:PHRX). The acquisition was previously announced on May 31, 2022, and was completed in accordance with its disclosed terms.
With the completion of the acquisition, Khiron has expanded its presence in Europe with an EU GMP-certified manufacturer and wholesaler and has gained a European manufacturing and distribution center for pharmaceuticals. The acquisition is an optimal complement for Khiron in Europe and is in-line with its economic asset-light strategy. As Khiron Europe's own wholesaler, the target will promote and sell Khiron's products directly to German pharmacies, which enables Khiron to control the whole value chain within the country and recognize an increased gross margin.
With this acquisition, Khiron is able to accelerate the expansion of its medical product portfolio with additional flower varieties which are in demand in the market and a THC-dominant full spectrum extract that combines the medicinal properties and areas of application of the established THC isolate formulations (dronabinol) with the specific advantages of a full-spectrum extract. Additional new products are already in the pipeline, that will comprise the entire spectrum of therapies with medical cannabis to be able to offer the right therapy for every patient, and more details will follow soon.
Pursuant to the terms of the acquisition, in consideration for the acquisition of all of the issued and outstanding shares of the target, Khiron issued to Pharmadrug 5.5 million common shares of the company and an additional 468,750 common shares in connection with certain closing adjustments for a total of 5.96 million common shares, as well as a non-interest bearing promissory note that was adjusted downward pursuant to certain closing adjustments to an aggregate principal amount of $974,137. The promissory note is payable one year from the date of issue in cash or, at Khiron's option, by the issuance of additional Khiron shares. Any issuance of Khiron shares on conversion of the promissory note will be subject to the prior approval of the TSX Venture Exchange.
A total of 5 million Khiron shares issued in connection with the closing are subject to a lockup agreement, pursuant to which Pharmadrug may not transfer such shares without Khiron's consent, with a quarter of the total number of shares subject to lock-up being released every 90 days following the closing date.
Photo by Jeff W on Unsplash
Related News
Benzinga CEO Predicts $1B In Cannabis Deals Closing In Just 2 Days In September: Find Out Where And How
Khiron Appoints Helen Bellwood (ACA) As Interim CFO
Medical Cannabis Company Khiron Continues Global Expansion Into Spain
Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX:KHRNF) (Frankfurt:A2JMZC) has completed the acquisition of Pharmadrug Production GmbH from Pharmadrug Inc. (OTCQB:LMLLF) (CSE:PHRX). The acquisition was previously announced on May 31, 2022, and was completed in accordance with its disclosed terms.
凯龙生命科学公司(多伦多证券交易所股票代码:KHRN)(法兰克福股票代码:A2JMZC)已完成收购的Pharmadrug生产有限公司,来自Pharmadrug Inc.(场外交易代码:LMLLF)(CSE:PHRX)。此次收购此前于2022年5月31日宣布,并根据其披露的条款完成。
With the completion of the acquisition, Khiron has expanded its presence in Europe with an EU GMP-certified manufacturer and wholesaler and has gained a European manufacturing and distribution center for pharmaceuticals. The acquisition is an optimal complement for Khiron in Europe and is in-line with its economic asset-light strategy. As Khiron Europe's own wholesaler, the target will promote and sell Khiron's products directly to German pharmacies, which enables Khiron to control the whole value chain within the country and recognize an increased gross margin.
随着收购的完成,Khron扩大了其在欧洲的业务,拥有一家欧盟GMP认证的制造商和批发商,并获得了一个欧洲药品制造和分销中心。此次收购是Khron在欧洲的最佳补充,符合其经济轻资产战略。作为Khron欧洲公司自己的批发商,该目标将直接向德国药店推广和销售Khron的产品,这使Khron能够控制该国的整个价值链,并认识到毛利率的增加。
With this acquisition, Khiron is able to accelerate the expansion of its medical product portfolio with additional flower varieties which are in demand in the market and a THC-dominant full spectrum extract that combines the medicinal properties and areas of application of the established THC isolate formulations (dronabinol) with the specific advantages of a full-spectrum extract. Additional new products are already in the pipeline, that will comprise the entire spectrum of therapies with medical cannabis to be able to offer the right therapy for every patient, and more details will follow soon.
通过此次收购,Khron能够加速扩大其医疗产品组合,推出更多市场需求的花卉品种和以THC为主的全光谱提取物,该提取物将已有的THC分离配方(Dronabinol)的药用特性和应用领域与全光谱提取物的特定优势结合在一起。更多的新产品已经在酝酿中,这些产品将包括医用大麻的全部疗法,以便能够为每个患者提供正确的疗法,更多细节将很快公布。
Pursuant to the terms of the acquisition, in consideration for the acquisition of all of the issued and outstanding shares of the target, Khiron issued to Pharmadrug 5.5 million common shares of the company and an additional 468,750 common shares in connection with certain closing adjustments for a total of 5.96 million common shares, as well as a non-interest bearing promissory note that was adjusted downward pursuant to certain closing adjustments to an aggregate principal amount of $974,137. The promissory note is payable one year from the date of issue in cash or, at Khiron's option, by the issuance of additional Khiron shares. Any issuance of Khiron shares on conversion of the promissory note will be subject to the prior approval of the TSX Venture Exchange.
根据收购条款,作为收购目标所有已发行及已发行股份的代价,KhIron向Pharmadrug发行了550万股公司普通股和额外的468,750股与某些收盘调整相关的普通股,共计596万股普通股,以及一张根据某些收盘调整向下调整的无息本金票据,本金总额为974,137美元。本票自发行之日起一年内以现金支付,或根据Khron的选择,通过增发Khron股票的方式支付。任何在转换本票时发行KhIron股票均须事先获得多伦多证券交易所创业板的批准。
A total of 5 million Khiron shares issued in connection with the closing are subject to a lockup agreement, pursuant to which Pharmadrug may not transfer such shares without Khiron's consent, with a quarter of the total number of shares subject to lock-up being released every 90 days following the closing date.
与成交相关发行的总计500万股KhIron股票须遵守锁定协议,根据该协议,Pharmadrug不得在未经Khron同意的情况下转让此类股票,受锁定的股票总数的四分之一在成交日期后每90天释放一次。
Photo by Jeff W on Unsplash
杰夫·W在Unspash上的照片
Related News
相关新闻
Benzinga CEO Predicts $1B In Cannabis Deals Closing In Just 2 Days In September: Find Out Where And How
Benzinga首席执行官预测9月份仅两天内就会有10亿美元的大麻交易完成:找出地点和方式
Khiron Appoints Helen Bellwood (ACA) As Interim CFO
希龙公司任命海伦·贝尔伍德(ACA)为临时首席财务官
Medical Cannabis Company Khiron Continues Global Expansion Into Spain
医用大麻公司KhIron继续在西班牙进行全球扩张
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧